News

Neurophyxia B.V. was incorporated on April 20th, 2008.

April 2008: Neurophyxia BV acquired ownership of the 2-IB patent estate, originally filed by Utrecht University from AM-Pharma.
July 2008: Pre-IND meeting with the US FDA
September 2008: Start of formal preclinical development of 2-IB (manufacturing and safety studies)
October 2008: Closing of first large financing round
January 2009: Granting of “Innovatiekrediet” loan by the Dutch Ministry of Economic Affairs.
February 2009: Granting of Orphan Drug designation by the US FDA.